A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-40
SponsorPT Bio Farma

About this trial

A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia

Eligibility criteria

Qualifiers

Clinically Healthy participants aged 18-40 years;

Participants have been informed properly regarding the study and signed the informed consent form.

Participants will commit to comply with the instructions of the investigator and the schedule of the trial;

Participants must have a negative IGRA and sputum.

Disqualifiers

Those who are currently diagnosed with tuberculosis or have a history of tuberculosis (positive IGRA or GenXpert sputum test or chest Xray suggestive of TB) and/or history of tuberculosis treatment; including TB Preventive Treatment (TPT);

There are serious chronic diseases, or the disease is in the advanced stage that cannot be controlled smoothly, such as diabetes and thyroid disease;

Currently suffering from or within 2 years of any of the following serious diseases, such as: advanced tumor, autoimmune disease, progressive atherosclerosis, acute exacerbation of the chronic obstructive pulmonary disease, acute or progressive liver or kidney disease, congestive heart failure, etc.; based on interview with participants

Those with known or suspected (or high-risk) immune function impairments or abnormalities, such as those receiving more than 20mg/day of systemic glucocorticoids for 14 consecutive days within the last 4 weeks, immunosuppressants within 3 months, and Those who received protein preparations or blood products or plasma extracts outside the gastrointestinal tract within 3 months;

Trial design

Treatments tested in this trial

  • LipovaxinS4-EAH (Middle Dose)
  • LipovaksinS4-EAH (High Dose)
  • Placebo

Treatment groups

60 Participants
are divided into 3 treatment groups

Sponsors and collaborators

PT Bio Farma

Lead sponsor

Fakultas Kedokteran Universitas Indonesia

Collaborator

Dr Cipto Mangunkusumo General Hospital

Collaborator